The StockRadio.com Interview Transcript:

Interview with Kraig Biocraft Laboratories, Inc’s CEO: Kim K Thompson

Carl of StockRadio.com : Hello. Welcome to the stockradio.com. Today we have the pleasure of welcoming back one of America ‘s most exciting small cap companies, Kraig Biocraft Laboratories and we have with us the Company’s CEO, Kim Thompson. Kraig Biocraft Laboratories trades on the Over the Counter QB, under the symbol KBLB. And the Company’s website is www.kraiglabs.com and that’s K-R-A-I-G-L-A-B-S.com

Kim, it’s hard to believe it’s been 6 months, but welcome back.

Kim Thompson, CEO and founder, Kraig Biocraft Laboratories, Inc.: Thanks you Carl. It’s always a pleasure talking with you.

Carl: Kim, we’re glad you could join us again today and, now, we’ve had a lot of new subscribers come to the site, so, maybe, you could start off by just doing a highlight of the Company and maybe you could tell us a little bit more about what’s been going on over the last 6 months?

KT: Certainly. Well Carl, as you know, Kraig Labs is a biotechnology company focused on really revolutionary developments in material sciences and what we originally set out to do when we launched the company, in 2006, is to create and develop in the laboratory an industrial production platform for recombinant spider silk and the reason is that this particular spider silk that we’ve been aiming to produce is stronger and tougher than steel.

It’s really, in many ways, a miracle fiber and we’ve made a lot of progress, as you know, since launching the Company, including last year when we were able to announce that we successfully created a transgenic silkworm, which was spinning a recombinant fusion spider silk fiber; a fiber composed of both spider silk and silkworm proteins. It was a major breakthrough, which we announced jointly with the University of Notre Dame and, since that time, our pace of research and development, and movement towards commercialization, has accelerated very rapidly. So we are excited. It is among the first days of 2012 and I think that 2012 is going to be the greatest year yet for Kraig Labs and for the future of recombinant materials.

Carl: That’s great, Kim. So, let’s go back to June of last year. The Company got a credit agreement for $1.5 million. Now, that’s no easy feat in this economic climate. How important is that for the Company last year?

KT: Well, it was important to us last year and it’s of continuing importance for us here, in 2012. Essentially, that financing facility provides us with the financing that are necessary to keep our operations flowing and that’s really critical in this business.

In 2008 and 2009, we saw most of the smaller biotechnology companies around us collapse amid the financial crisis. These were companies which had fantastic concepts, which were moving rapidly towards executing their business plan and, unfortunately, as a result of the financial collapse, many of those products are never going to see the light of day.

We’ve been more fortunate than that, we’ve always had the backing of financiers who believed in what we’re doing. I think that’s the case here, with the agreement you’re referring to and it provides us with, frankly, a certain base comfort level, as we move into 2012, that we’ve got our, some of our financial needs met. That, frankly, is essential to move a biotechnology project forward.

Carl: In November you signed a commercial agreement with the University of Notre Dame. Maybe you can tell us what that means, as well, for the Company and the future of your products?

KT: Well, that was a critical agreement for us, and Carl as you know, Kraig Biocraft Laboratories does almost all of its scientific development work inside universities and most particularly within the laboratories on campus at the University of Notre Dame and the agreement you referenced is an exclusive commercial license given to us by the University of Notre Dame, which grants us the exclusive right to commercially exploit the technologies which we developed inside their laboratories.

Another critical aspect of that agreement was that it made the University of Notre Dame a shareholder in Kraig Labs for the first time.

We’ve been working cooperatively with the University for many years, but this agreement is the first time that they’ve really formally become a part of the Company, in the sense of becoming a minority shareholder, and this commercial agreement relates to another material which our shareholders refer to as “Monster Silk” our recombinant spider silk product, which we developed within the University of Notre Dame.

And, then, one other thing, Carl, I should add, while we’re on the same point, was the agreement we had signed earlier in the year with Sigma-Aldrich Corporation. Sigma is a biotechnology giant, by virtue of that agreement; they also became a minority shareholder in Kraig Laboratories. So we’re, frankly, thrilled to have that kind of institutional involvement in our company, University of Wyoming , University of Notre Dame, Sigma all on as, frankly, minor share holders in the company. More importantly that Sigma-Aldrich agreement gave us access to Sigma’s zinc finger nucleus technology, this is a very powerful genetic engineering technology, which has allowed us, since signing that agreement, to significantly ramp up and accelerate our research and development on the next generation of materials beyond “Monster Silk”, and in that regard we’ve already been able to announce earlier in 2011 our creation of seven new transgenic lines using zinc finger nucleus technology.

I’ve just recently received a report from the laboratory that a number of additional transgenic lines have also been created using the ZFN technology, and we believe we are in a very advanced stage of development of the next generation of spider silk polymers, which is essentially not a fusion polymer as we created with the “Monster Silk”, but something more along the lines of a purer spider silk polymer composed entirely or almost entirely of spider silk proteins. Not to get into too much detail here, we also believe that this has significantly accelerated our development of the generation three technology, which essentially is a customizable polymer. A fiber to which we can customize, depending upon the requirements and specifications of an end customer.

This has been a rather significant improvement and advancement of our company, both on the scientific front and in the terms of its commercial prospects.

Carl: That’s so exciting for the company. At the beginning of last month according to your own words, “A major milestone was reached by the company” can you tell us about that?

KT: Certainly, I think what you’re referring to, were the filing of our first international patent applications. That was certainly a significant jump for the company. The patent applications were filed by the University of Notre Dame, covering to technology described as our “Monster Silk” technology and various methodologies to produce both transgenic silkworms and along with the utility and end uses for the “Monster Silk” product. The patent applications were filed by the University of Notre Dame in Geneva , and of course that dove tails in with the exclusive commercial license agreement we received from the University, which covers the technology described in those patents.

So I must say that was a very exciting time for us, here at Kraig Labs, and the filing of the patent application involved the opening of a champagne bottle here. But, frankly, more exciting to us, than the filing of the applications, has been the progress that’s been made in the labs since then. Essentially, we have to give credit where credit is due here, and that is to Sigma’s zinc finger technology, that has really allowed us to significantly accelerate our research and development.

Looking back at “Monster Silk”, which is, I think a very exciting product and exciting scientific achievement. In fact, Carl, I can inform you as of this morning a scientific article has just been published by the National Academy of Sciences, describing our work in creating these transgenic silkworms producing recombinant spider silk. But looking back on the development of “Monster Silk”, we did that with out the zinc finger technology, we did that using a technology known as piggy back, which was developed largely by a member of our scientific advisory board Dr. Malcolm Frasier. With this new ZFN technology we can move much faster and much quicker towards our goal, and that’s being born out of the laboratory right now.

Carl: That’s fantastic. Now Kim here we sit on the first day of 2012, and as you said it’s going to be an exciting year for the company, if you’re able to, can you tell us if we’re going to be able to see spider silk going into production at all this year?

KT: I believe so. I believe that our first generation product, which we, as you know we refer to as “Monster Silk”, I believe that will go into production in 2012 and to be clear we are in production right now with “Monster Silk” in the laboratory. But we’re operating within the university laboratory system, and they’re not set up, of course, for commercial production; but I believe that we will see, and it is our goal to see actual commercial industrial skill production of “Monster Silk” in 2012; and our goal is also to achieve significant laboratory production of the next generation of fibers also in 2012.

Carl: Kim that will be exciting to see going into full production. So also on the note of 2012, what are some of the other goals that you’re hoping to have for the company?

KT: What comes to mind right off the bat for 2012 is, 1) moving “Monster Silk” into industrial production, 2) in the lab, completing our research and development and actually beginning laboratory production of our second generation of pure spider silk product, and 3) M & A, we believe moving forward that 2012 may provide an excellent opportunity for M & A as it would advance our execution of our business plan.

Carl: Great Kim, it’s always great speaking to you, it’s such an exciting company. Again we’ve been speaking to Kraig Biocraft Laboratories and its CEO Kim Thompson. The company trades on the OTCQB under the symbol KBLB and the company’s website is www.kraiglabs.com , and that’s K-R-A-I-G-L-A-B-S.com. Kim, once again thank you so much for your time today.

KT: Thank you Carl.

____________________________________________________

About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com) is a fully reporting biotechnology company that has achieved a series of scientific breakthroughs with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this interview about the Company’s future, expectations and business plans, other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

LANSING, MI — (Marketwire) — 11/14/11 — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (PINKSHEETS: KBLB) (the “Company” or “Kraig”) announced that researchers at the University of Notre Dame, utilizing customized zinc finger configurations licensed to Kraig from Sigma-Aldrich, succeeded in creating seven or more strains of transgenically modified silkworms.

The Company believes that this breakthrough removes the largest barrier to pure spider silk technology.

The zinc finger nuclease were designed to cleave the silkworm’s native heavy chain gene. The resulting silkworms were inter-mated to produce 50 mating pairs, which each produced clutches of approximately 100 eggs. Genetic testing designed to detect mutations at the site of zinc finger cleavage were preformed and the testing recovered positive results for zinc finger disruption, therefore knockout of the native heavy chain gene in embryos, from 7 of the first 13 mating pairs, analyzed.

“This success rate is much higher than we ever expected,” said Company CEO and founder Kim Thompson. “The laboratory reports that seven new strains of transgenics have been confirmed so far.”

“The bottom line is that zinc finger nuclease works exceedingly well for our particular targets. Our adopting this technology was a bit of a gamble at the time, but it turns out to have been one of the smartest moves we could have made. We view this genetic knockout as the achievement of our greatest scientific goal for 2011,” continued Thompson.

Dr. Malcolm Fraser reported, “We anticipate that we will be able to recover homozygous knockout silkworms from these pools of embryos with little difficulty. These homozygous commercial strain heavy chain knockouts will serve as a more effective platform technology for rapid development and commercialization of future spider silk transgenics, allowing us to readily recover commercially ready spider silk transgenics by simply screening for the production of cocoons.”

Dr. Fraser concluded, “This Zinc Finger approach exceeded our best expectations in terms of its capabilities for introducing mutations in silkworms. The frequency of mutation events and the capability of working directly with the commercial strains give a much more rapid route to new, commercially relevant transgenics.”

The Company believes that the next generation of its technology, which utilizes zinc fingers, will significantly expand its product capabilities and target markets.

Thompson further stated, “Dr. Fraser and his team have once again verified our scientific models. The results also serve as proof of efficacy for the creation of targeted transgenics, and confirm our confidence in the power of zinc finger technologies. We now believe that we have both the platform and targeted transgenic capabilities which we need to create Generation II and Generation III technical textiles.”

The Company is already ramping up production of Monster Silk, its previously disclosed product which is the subject of the Company’s recent licensing agreement with the University of Notre Dame. While Monster Silk is targeted for conventional applications, the Company believes that the technology described in today’s announcement will ultimately unlock applications for technical textiles and broader markets.

About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com) is a fully reporting biotechnology company that has achieved a series of scientific breakthroughs with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

Contact:
Ben Hansel, Hansel Capital
(720) 288-8495

LANSING, MI — (Marketwire) — 11/03/11 — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (KBLB) (the “Company” or “Kraig”) announced that it signed a commercial license agreement with the University of Notre Dame regarding spider silk technologies.

The agreement awards Kraig the exclusive worldwide commercial rights to certain spider silk technologies which the Company jointly developed with the University of Notre Dame. Pursuant to the agreement, the University of Notre Dame will become a shareholder of the Company. The University will also receive a 2% royalty of the Company’s net sales of products which incorporate the technology.

The subject of the agreement is the definitive spelling out of rights for the commercialization of what the Company refers to as “generation one” spider silk technology. The agreement confirms the Company’s exclusive right to the commercial development of spider silk textiles derived from the subject technology.

“Due to the significance of this technology it was important that we craft an agreement that benefits Kraig, our shareholders and the University,” stated Kim Thompson, Company CEO and founder. “We are very happy to welcome the University of Notre Dame as our newest shareholder. We are also very happy to formally consummate this commercial license agreement covering the commercial rights to this exciting technology which we have been developing with the University.”

“Our collaboration with university laboratories has been fundamental to the rapid progress we have made in the development of spider silk,” Thompson continued. “The commercial license agreement reflects that sentiment and lays the groundwork for the Company’s commercialization of spider silk technologies.”

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com) is a fully reporting biotechnology company that recently achieved a series of scientific breakthroughs, with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

Contacts:

Ben Hansel
Hansel Capital
Email Contact
(720) 288-8495

LANSING, MI — (Marketwire) — 08/08/11 — Kraig Biocraft Laboratories, Inc. (KBLB) announced that researchers working with the Company recently completed the second round of micro-insertions using zinc finger technology. The use of the zinc finger technology in the second round is designed to further enhance Kraig’s previously disclosed Monster Silk polymers.

“This round of micro-insertions is focused on further modifying and advancing the capabilities of our ‘Monster Silk’ caterpillars,” said CEO Kim Thompson. “In the second round, the zinc finger technology is being used to modify one of the company’s transgenic lines of silk worm that are already producing recombinant spider silk. This work represents a significant step forward from our first round of zinc finger micro-insertions.

“We are so confident in the technology,” continued Thompson, “that we advanced to the second round of micro-insertions even while we are still awaiting a definitive report on the first round.”

The current second round is focused on two objectives: 1) modifying the profile of the expressed proteins in the previously disclosed “Monster Silk” fiber, and 2) potentially creating a new recombinant silk platform technology.

“We are very happy to see this work progressing so quickly,” said Thompson. “As I have previously noted, we are monitoring the results of round one, and now of round two, very closely. We are very optimistic that we will be able to announce results from the first round in early Fall, and results from the second round, in approximately the middle to late Fall.”

In April, Kraig entered into an agreement with Sigma-Aldrich to use Sigma’s powerful zinc finger technology to accelerate Kraig’s scientific research and product development. The zinc fingers are an effective genetic engineering technology that the Company is using to create the next generation of biomaterials, including recombinant spider silks, for the textile and technical textile markets.

About Kraig Biocraft Laboratories
Kraig Biocraft Laboratories is a fully reporting biotechnology company that recently achieved a series of scientific breakthroughs, with implications for the global textile industry. For further information, please visit www.KraigLabs.com.

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

Contact:

Ben Hansel, Hansel Capital, LLC
(720) 288-8495

The Company’s First Zinc Finger Technology Silkworms Achieve High Hatch Rate

LANSING, MI — (Marketwire) — 07/05/11 — Kraig Biocraft Laboratories, Inc. (KBLB) announced the completion of its first round of zinc finger micro-insertions.

“We are very excited to be performing these genetic engineering feats so soon after signing the agreement for their use with Sigma-Aldrich,” said CEO and company founder, Kim K. Thompson. “The immediate results from this first round of generic insertion are truly encouraging, as we observed a high hatch rate within a few days of employing the new technology.”

In April, Kraig entered into an agreement with Sigma-Aldrich to use Sigma’s powerful zinc finger technology to accelerate Kraig’s scientific research and product development. The zinc fingers are an effective genetic engineering technology that the Company is using to create the next generation of biomaterials, including recombinant spider silks, for the textile and technical textile markets.

“The company has very high expectations for these newly hatched silkworms and we are watching their development closely,” Thompson continued. “As of yet, the caterpillars are far too small for us to determine whether we hit our genetic target. So far, the technology is performing as anticipated and, even as we monitor the development of these silkworms, we are preparing for the next round of micro-insertions.”

About Kraig Biocraft Laboratories

Kraig Biocraft Laboratories is a fully reporting biotechnology company that recently achieved a series of scientific breakthroughs, with implications for the global textile industry. For further information, please visit www.KraigLabs.com.

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

Contact:
Ben Hansel, Hansel Capital, LLC
(720) 288-8495

LANSING, MI — (Marketwire) — 06/30/11 — Kraig Biocraft Laboratories, Inc. (KBLB) announced that the Company has entered into a new financing agreement with Calm Seas Capital.

The new credit facility supplements the existing agreement with Calm Seas Capital and provides for up to $1.5 million over a 24 month period.

“Calm Seas has been a solid funding source and their new expanded capital commitment strengthens Kraig’s position, as we move forward,” stated Kim Thompson, the Company’s CEO and founder. “The new credit facility signifies an important step in executing our commercialization plan and the proceeds will enhance our capacity to pursue the ramp-up phase of our recombinant product.”

The financing agreement with Calm Seas Capital was recently disclosed in an 8k filing and that filing, including details of the agreement, are available on the EDGAR system.

About Kraig Biocraft Laboratories

Kraig Biocraft Laboratories is a fully reporting biotechnology company that recently achieved a series of scientific breakthroughs with implications for the global textile industry. For further information, please visit www.KraigLabs.com.

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

Contact:
Ben Hansel, Hansel Capital, LLC
(720) 288-8495

June 2011

Mark Marek of Chartpoppers.com: Hello, welcome to Chartpoppers. Today we’re joined by CEO Kim Thompson of Kraig Biocraft Laboratories. Kraig Biocraft Laboratories trades, and is quoted on the Over the Counter QB, under the symbol KBLB.

Kim, thanks for coming back to the show and updating us on the company.

Kim Thompson, CEO and founder, Kraig Biocraft Laboratories, Inc.: It’s my pleasure Mark.

MM: Kim, we do appreciate you taking the time out.

I know that you’re a very busy man. You get a lot of calls since you cracked the code, but could you maybe spend a little time and tell us about how things have progressed since you made that announcement about six months ago and what developments have been in the Company?

KT: Absolutely, for your listeners who may not be familiar with the Company let me give a little bit of recap. In fact, when we last did an interview, Mark, it was shortly before we made that announcement with the University of Notre Dame and, essentially, what Kraig Biocraft Laboratories has been doing for the last several years, is working cooperatively with the University of Notre Dame to produce recombinant silk fibers.

Essentially, what we’re doing is genetic engineering work, to try to create a platform for industrial scale production of recombinant silk fibers with similar mechanical characteristics to those found in nature, in spider silk. A material which is stronger, tougher than steel, highly flexible, which has physical and mechanical properties which are, in some ways, unmatched by materials which man can currently produce, and we really, I’m happy to say, back in September we were able to announce that we had largely achieved those goals.

In working cooperatively with the University, we were able to announce that we created approximately twenty different strains of transgenic silkworm, which we created using spider silk DNA sequences and that these silkworms were spinning recombinant silk, which was a fusion of spider silk and native silkworm silk and we announced, also at that joint press conference, that one of these silks, in particular, which we are tentatively calling “Monster Silk” was demonstrating physical properties of strength and elasticity, which significantly exceed that of natural silkworm silk. So, this was a major milestone for the Company, but a lot has happened since then.

What I can now reveal here in this interview, because we actually issued a press release about it, is that shortly after that announcement we entered into negotiations with one of the world’s largest and most powerful biotechnology companies, Sigma-Aldrich, and we entered into negotiations with them in order to acquire licensing rights to use their very powerful Zinc Finger technology in our laboratories.

It’s taken months to finalize that agreement, but we actually signed with them on April 8 and we are now introducing the Zinc Finger technology into our laboratory.

Sigma is currently designing and building customized Zinc Fingers for our use and this is and incredibly powerful technology, which will greatly accelerate our research and development efforts and also give us capabilities, which simply would have been impossible with any other technology.

It’s also, from our perspective, something of a stamp of approval. Sigma came in and did due diligence on our Company, sent scientists into our lab to make sure our technology was solid before signing the deal with us and that was really the first time we let an outside company come in and actually put a scientist in our lab and review what we’ve done and what we’ve accomplished.

That was a very big deal for us. Sigma’s now a minor shareholder of Kraig Biocraft Laboratories, as a result of this transaction, and we do anticipate that it will rapidly speed up our development of the next generation of products.

MM: Kim, could give us a little more understanding in what the technology that Life Science brings to the table enables you to do?

KT: To describe this technology that we’ve acquired through this licensing agreement with Sigma, it’s going to be little difficult for those who aren’t intimately familiar with the workings of biotechnology, but, in essence, and, this going to be a little more detailed than you want, but, in essence, this technology, this Zinc-Finger technology with Sigma, will allow us for the first time to make changes in the silkworm DNA that were completely impossible to make before. In the past, these genetic engineering technologies were almost like throwing darts at a gigantic dart board from a distance of, maybe, 200 yards and, in order the make the changes that you wanted, you would have to throw those darts really hard. You might have to throw 10,000 of them to get even close to your target and you probably would never get exactly get to your target, but you could get close. With 10,000 tries you might get lucky and get close.

With this Zinc-Finger technology, it’s actually possible to walk right up to the dart board and push the dart in exactly where you want it the first try; the very first try.

To say that, and this is just my own thinking, but my own thinking here is that this will accelerate our product development by a factor of 50.

Instead of 10,000 tries to create a new recombinant silk fiber with extraordinary properties, we should be able to design the sequence, walk up to that dartboard and make that edit, make that change.

It’s almost like editing a document in Microsoft Word. Go into the document, you see a word that’s misspelled, you can change it. You want to change a period to a question mark, you can change it.

For the first time, this technology will give us the ability to do that with silkworm DNA. So, it’s incredibly powerful. We’re very excited. The deal’s almost been six months in the works, but it’s six months that I think are really going to pay off for Kraig Labs and its shareholders.

MM: Back in December 2010 you released a video, which deals with the basic technology of spider silk. I think it’s important to mention that, because it could be a little hard to wrap your hands around the significance of these findings. Could you maybe give us a link or direction to that video?

KT: Probably the best, there have been several videos that we produced or that have been produced by, for example, the University of Notre Dame, on this technology. I would suggest going to the Company’s website and going to our news page or our video page. There you can find links to several news stories and videos describing what we’re doing. All of those videos predate the signing of Sigma deal, but you can certainly get an idea of the nature of the technology and what it is that we’ve accomplished, and what we’re doing.

The website is www.KraigLabs.com . Those videos are available there and what you can see on those videos is actual silk fibers that we’ve produced, the recombinant silk fibers, using spider silk DNA.

You can see the genetic engineering technologies. You can see our genetically modified silkworms and, of course, you can see me and some of the scientists that have been working at Notre Dame on this project for the last several years.

I know, to many people who just learned Kraig Labs since September, it appears like we arrived on the scene overnight and we formed a company and created this transgenic silkworm, but it’s actually been many, many years in the works.

There’s been a lot of elbow work. A lot of hard work and effort by Kraig Labs and the University of Notre Dame to bring us to where we are now, which is a point where we actually have not just research and development, but actual product and are gearing up towards actual commercialization.

MM: Again, the Company is Kraig Biocraft Laboratories. The symbol can be found on the Over the Counter QB, under the symbol KBLB.

Kim, we’re very excited to be following the Company during this crucial time. It’s been a pleasure and thanks for speaking with us and we look forward to checking in a few months and just see where you are with the spider silk.

KT: Mark, it’s been a pleasure, and we haven’t forgotten that you came to interview us, even before we had the breakthrough announcement in September.

You know, since that time, we’ve obviously garnered a lot of interest and we received a lot of calls, but before that breakthrough announcement, we were relatively obscure and we haven’t forgotten that you initiated some coverage of us before we were known and it’s been a please to do another interview with you.

MM: Thank you very much, Kim. Have a good day.

Independent Testing Confirms That the New Hybrids Are Producing Recombinant Silk Which Significantly Exceeds Traditional Silk in Both Elasticity and Tensile Strength

LANSING, MI, May 31, 2011 (MARKETWIRE via COMTEX) — Kraig Biocraft Laboratories, Inc. (PINKSHEETS: KBLB) announced that it successfully mated its transgenic silkworms, which produce recombinant spider silk, with a physically larger commercial strain of the domesticated silkworm. The resulting hybrid silkworms are larger than Kraig’s original transgenic silkworms and are also producing significantly larger recombinant silk cocoons.

Independent laboratory testing confirmed that the transgenic/commercial silkworm hybrids are producing silk which is significantly stronger and more flexible than that of the original commercial strain. The new recombinant spider silk is a composite silk composed of both native silkworm silk proteins and spider silk proteins (as in the original Kraig transgenic silkworm whose development was announced in late September).

Kim Thompson, the Company’s CEO and Founder, stated, “The new hybrid was specifically designed for commercialization and has been designated ‘Monster Hybrid,’ which is the successful cross between our transgenic silkworms and a much larger commercial strain.

“The result is a large, robust, commercial sized silkworm which spins a larger commercial sized cocoon composed of recombinant spider silk like the original transgenic. The new hybrid was specifically designed to generate greater recombinant silk production capacity than our original first generation transgenic.”

“This larger hybrid transgenic will be the platform for our commercialization ramp up,” Thompson continued. “Now that the strength and elasticity qualities have been confirmed, we can move forward with cultivating the hybrids in commercially viable quantities. We are working diligently to increase our stock of the new strain in order to increase our production capacity.”

About Kraig Biocraft Laboratories

Kraig Biocraft Laboratories is a fully reporting biotechnology company that recently achieved a series of scientific breakthroughs, with implications for the global textile industry. For further information please visit www.KraigLabs.com .

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

Contact: Ben Hansel (720) 288-8495

LANSING, MI, May 25, 2011 — Kraig Biocraft Laboratories, Inc. (PINKSHEETS: KBLB) announces today that Kim Thompson cordially invites all interested parties to participate in the Company’s conference call to be held on Friday, June 10, 2011 at 4:30 p.m. EDT.

Thompson, the Company’s CEO and Founder, will review the recent Sigma-Aldrich agreement and upcoming laboratory developments, as well as what is in the recombinant spider silk commercialization pipeline, followed by a question and answer period.

The conference call phone number and other details, including access codes, will be announced in a follow-up company release on the morning of the call. Shareholders are invited to submit questions to benh@ttfsco.com and must be received by Thursday, June 9, to be considered.

About Kraig Biocraft Laboratories

Kraig Biocraft Laboratories is a fully reporting biotechnology company that recently achieved a series of scientific breakthroughs, with implications for the global textile industry. For further information please visit www.KraigLabs.com .

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

Contact: Ben Hansel (720) 288-8495

Sigma-Aldrich and Kraig to work together to create the next generation biomaterials.

Sigma-Aldrich Becomes Kraig Shareholder

  LANSING , MI –4/12/2011 – Kraig Biocraft Laboratories, Inc. (Pinksheets: KBLB) announced today that the Company has entered into a licensing agreement with biotechnology giant Sigma-Aldrich (NASDAQ: SIAL), Inc.

Kraig has successfully negotiated a license to use Sigma-Aldrich’s powerful zinc finger technology to accelerate its scientific research and product development, along with an option to commercialize the resulting biomaterials in the textile and biomedical fields.

“Sigma-Aldrich’s proprietary zinc finger technologies are extremely powerful tools which enable very precise genetic targeting,” said Kraig’s CEO Kim Thompson. “We are convinced that this technology is the key to creating advanced new products and materials. We believe that when these customized tools are delivered by Sigma in the coming weeks, the technology will enable us to rapidly and precisely target specific gene sequences for the creation of stronger fibers, advanced textiles and new bio-materials.”

“ZFN technology has been revolutionary in genome engineering for various applications, including animal models of disease, engineering of biopharmaceutical production systems, academic research and therapeutics,” said Dr. Joseph Bedell, Director of Sigma’s Commercial Animal Technology Group. “Spider silk production is just the first example of a commercial animal application for this exciting technology.”

“Kraig has the utmost confidence in the power of Sigma’s zinc finger technology,” said Mr. Thompson. “Sigma’s agreeing to provide this technology by virtue of the licensing agreement to Kraig, is a real boost for us, and for the future of bio-materials and spider silk technology. We negotiated this agreement not only to accelerate our development of advanced materials, but also because I believe that Sigma’s zinc finger technology will reinforce Kraig’s competitive advantage in the field of bio-materials and advanced silk polymers. Kraig Biocraft Laboratories expectation is that the combination of Sigma-Aldrich’s revolutionary technology and know-how, coupled with Kraig’s proprietary bio-materials technology and know-how, will create synergies that will benefit both companies.

About Sigma-Aldrich

Sigma- Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma- Aldrich operates in 38 countries and has 7,900 employees providing excellent service worldwide. Sigma- Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com .

About Kraig Biocraft Laboratories

Kraig Biocraft Laboratories is a fully reporting biotechnology company that recently achieved a series of scientific breakthroughs, with implications for the global textile industry. For further information please visit www.KraigLabs.com .

Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops,” “researching,” “research,” “potential,” “implications,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

Contact:
Ben Hansel
(720) 288-8495 benh@ttfsco.com

See Sigma-Aldrich’s related press release